Rubicon Research Ltd.

₹663.4

-12.2 (-1.8%)

RUBICON Share Price

Pharmaceuticals & Biotechnology

As on January 19, 2026

Sector

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 0 Cr

P/E Ratio76.1

Dividend YieldN/A

Trendline Performance

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	674.42	Bearish
10-DMA	671.62	Bearish
20-DMA	672.78	Bearish
50-DMA	660.18	Bullish
100-DMA	---
200-DMA	---

Historical Performance

1 Year

N/A

3 Years

N/A

5 Years

N/A

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	12,843	8,539	3,935	3,136	3,147
Total Expenditure	10,283	6,993	3,750	3,528	2,231
Other Income	119	185	255	168	101
Operating Profit	2,679	1,731	440	-224	1,018
Interest	368	313	190	97	94
Depreciation	366	390	361	340	293
Profit Before Tax	1,945	1,029	-110	-661	631
Consolidated Net Profit	1,344	910	-169	-671	307
Adjusted EPS	9	6	-1	-4	2

Compounded Sales Growth

10 Years:81.5

5 Years:37.3

3 Years:32.6

TTM:8.5

Compounded Profit Growth

10 Years:263.3

5 Years:22.1

3 Years:-7.1

TTM:8.1

Stock Price CAGR

10 Years:N/A

5 Years:N/A

3 Years:N/A

TTM:N/A

Return on Equity

10 Years:N/A

5 Years:2

3 Years:-1.1

last year:8.7

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	154	152	51	51	51
Total Reserves	4,993	3,460	2,667	2,881	3,569
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	1,226	1,511	1,020	706	529
Other Current Liabilities	930	751	458	328	334
Short Term Borrowings	2,901	2,642	1,958	914	435
Total Liabilities	14,497	11,086	7,497	5,595	5,383
Capital Work in Progress	67	96	245	26	57
Long Term Loans & Advances	409	157	131	282	59
Currents Investments	---	---	---	---	138
Short Term Loans and Advances	381	536	315	177	127
Total Current Assets	10,634	7,632	5,016	3,284	3,363
Total Assets	14,497	11,086	7,497	5,595	5,383
Adjusted Book Value	33	24	18	19	24

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 76.1, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered price CAGR data is unavailable.
The stock carries a high beta of 1.4, implying higher volatility and elevated risk.
In the last financial year, the company reported an EBITDA of ₹2679 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹12843 million, indicating a large and established business.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1056033.1

No. of Shares: 1592 (Approx)

Performance:5.6%

P/L: ₹56033.1

NIFTY Performance: 9.6%

1 day Top Gainers